Dynatronics said late last month it tapped former NinePoint Medical CEO Christopher von Jako as its new chief executive officer and board member, succeeding Kelvyn Cullimore Jr. who will stay on the company’s board of directors.
Prior to joining Dynatronics, von Jako acted as prez & CEO of NinePoint Medical. Before joining Nine Point, von Jako also served as prez & CEO of NeuroTherm, prez of ActiViews and held positions with medtech companies including Integra LifeSciences, Covidien and Medtronic.
“After thorough succession planning and a comprehensive search process, the board is pleased to have found the best individual to assume leadership of this organization. This was the culmination of a rigorous succession process that the board initiated several months ago. Chris has a track record of proven leadership across multiple organizations. His experience will help shape important strategic decisions for the organization going forward. Also, on behalf of the board, I would like to thank Kelvyn Cullimore, Jr. for his many years of service to Dynatronics and the many contributions he has made in positioning the company for an exciting new chapter of growth,” board chair Erin Enright said in a prepared statement.
“I’m honored and grateful to the board for the opportunity to lead this organization. There is an exceptionally talented team at Dynatronics that is focused on growing the business and helping shape the physical therapy, athletic training, and orthopedic markets. I’m excited to join Dynatronics at this pivotal point in the company’s history,” von Jako said in a press release.
Dr. Turk serves as a practicing physician at the Medical University of South Carolina, and will join Dr. Aaron Grantham who serves as the company’s cardiovascular CMO.
“I am pleased to welcome Dr. Turk to the Corindus team. His guidance and expertise will be critical as we expand our focus and technology to include treatment for neurovascular interventions. We strongly believe that our technology pipeline can add value across the spectrum of vascular interventions, with remote access and advanced robotic capabilities at the forefront of our strategy,” prez & CEO Mark Toland said in a prepared statement.
Corindus also announced it formed a physician steering committee dedicated to neuroendovascular procedures slated to be led by Dr. Turk.
“I look forward to partnering with the Corindus team and the company’s Neuroendovascular Steering Committee to bring robotic treatment to neurovascular care. I believe that robotics will be critical to transforming the treatment paradigm for the neurovascular space. Speeding up treatment time through remote access capabilities and robotic precision will revolutionize how patients with illnesses such as acute stroke receive treatment,” Dr. Turk said in a press release.
The hires follow the Foxborough, Mass.-based company’s acquisition of Integer’s advanced surgical and orthopedics business, the company said.
Crowley preveiously served as Medtronic’s minimally invasive therapies group global operations VP, while Smyth previously spent 15 years as an exec in commercial, operations and engineering management roles at Integer.
“I am very excited about these newest additions to our management team. With our recent acquisition of Integer’s AS&O business, Viant has doubled in size and significantly expanded our capabilities and offerings. Sean and Declan bring to our team a great mix of industry expertise and experience that will contribute significantly to our goal of being the provider of choice to the world’s leading medical device OEMs,” CEO Brian King said in a press release.
Myomo said this week it hired Micah Mitchell as its new chief commercial officer.
Prior to joining Cambridge, Mass.-based Myomo in the newly created chief commercial officer position, Mitchell served in sales management and executive roles at Invacare, Alliance Seating and Mobility and Apria Healthcare.
“Now that we have embarked on scaling up our commercial operations to bring the MyoPro to the many people who could benefit from this life-changing product line, we are pleased to have an executive of Micah’s stature join our senior management team. He has a track record of growing revenues, and he will collaborate with our chief marketing officer, chief medical officer and operations management to develop and implement programs that provide the MyoPro to a greater number of patients through our clinical channel partners,” CEO Paul Gudonis said in a press release.
Pavmed (NSDQ:PAVM) said today it named Shaun O’Neil as its first chief commercial officer, set to take effect on July 23.
Prior to joining Pavmed, O’Neil held positions with AngioDynamics including regional sales manager for its peripheral vascular division. Before joining AngioDynamics, he also held marketing, sales and engineering roles at Aycan Medical Systems.
“I am incredibly excited to welcome Shaun O’Neil to the Pavmed team. As Pavmed approaches important regulatory and commercial milestones, the time has come to begin laying the foundation for our transition from a development-stage to a commercial-stage company. I am confident Shaun is the best person to lead this effort. Dr. Brian deGuzman, Pavmed’s chief medical officer, Michael Glennon, our vice chairman, and I have been direct witnesses to Shaun’s industry savvy, leadership skills, vision, work ethic, professionalism and integrity since AngioDynamics first joined us in discussions that led to its acquisition of our first company, Vortex Medical, and its groundbreaking, life-saving AngioVac device. AngioVac is a challenging device to commercialize, with multiple specialty call points and the need for intense clinical support. Shaun played a critical role in establishing a vision and plan for AngioVac’s commercialization and successfully executed on that plan with his team. We observed that he is equally as comfortable in the board room crafting strategy as he is in the trenches with his sales reps calling on physicians and hospitals to adopt a new, groundbreaking technology for the benefit of their patients. That professional versatility, drive to excel and commitment to patients aligns perfectly with our business model and company ethos,” CEO Dr. Lishan Aklog said in a press release.
“I have watched with keen interest as this unique and disruptive company has made remarkable progress since its founding by a team that I learned to respect and admire over several years of working closely on the commercialization of AngioVac. I am very excited to join Pavmed as it approaches the expected commercial launch of two highly innovative products with billion-dollar market opportunities. I enthusiastically accepted Dr. Aklog’s offer to join this highly accomplished team because I have been a true believer in its vision and business model since its inception, and because I believe the company’s lead products have all the hallmarks of commercial blockbusters that will benefit many patients worldwide while creating significant value for Pavmed’s shareholders. I have spent a substantial part of my career providing physicians and their patients with less invasive and more cost-effective solutions for unmet clinical needs. In CarpX and EsoCheck, I see two products with great potential to transform the care of patients with highly prevalent and debilitating or life-threatening conditions. Pavmed has the cash runway and streamlined business model that I believe will allow us to build tailored commercialization platforms for each product that will be ready to activate upon regulatory clearance,” O’Neil said in a prepared statement.